Genomics Market (2024 - 2030) Size, Share & Trends Analysis Report By Application (Functional Genomics, Epigenomics, Pathway Analysis, Biomarker Discovery, Others), By Technology, By Deliverable, By End-use, By Region, And Segment Forecasts

Genomics Market Summary

Moreover, increasing number of joint ventures and partnerships amongst market players is also expected to have a positive impact on the genomics market growth. For instance, in June 2022, Illumina, Inc., and Allegheny Health Network signed a collaboration for effective evaluation of the impact of in-house Comprehensive Genomic Profiling (CGP) to leverage patient care. The COVID-19 pandemic outbreak had posed challenges to applications of genomics technology in terms of research and therapeutics. Nevertheless, some niche applications were of great use to mankind during the pandemic situation to facilitate immediate attention for designing effective diagnostics, effective therapeutics and steps to curb the spread of COVID-19.  For example, the viral genome mutational rate (~1-2 bases per month) was gauged for validity of PCR cycle was estimated to understand the efficacy of the re-purposed anti-viral treatments and thereby the vaccine development process was streamlined.

Many genomic surveillance programs were launched country wise to understand the dynamics of pandemic situation and to effective preventive measures. For instance, in December 2020, the Indian SARS-CoV-2 Genomics Consortium (INSACOG) was launched by the joint efforts of Department of Biotechnology (DBT), Ministry of Health, and ICMR with an aim to screen the genomic variations in the SARS-CoV-2 by sequencing technologies. Furthermore, country specific companies are providing consumer genomics services which is also expected to fuel the market size in coming years. One such company being Mapmygenome which is one of the pioneers in India offers DTC genomics services.

The increasing prevalence of inherited cancers is expected create a high demand for cancer genomics. The substantial understanding of human genome have targeted focus on use of various gene therapies for treatment of cancers by modern gene editing techniques such as CRISPR-Cas gene technology. For instance, in September 2022, a group of researchers at the University of California introduced the applications of precision genome editing agents for management of inherited retinal diseases (IRDs).

The development of high-throughput sequencing technologies such as Next-Generation Sequencing (NGS) and microarrays has generated massive amounts of genomic data. However, the rapid accumulation of this data from DNA sequencing and Electronic Health Records (EHRs) poses significant challenges and opportunities for the extraction of biologically or clinically relevant information. Phenome-wide association study (PheWAS) & genome-wide association study (GWAS) are helping researchers to study correlations between genotype and phenotype.

The market players are extensively working towards collaborations, expansions, acquisitions and huge capital investments to advance in research to understand rare diseases and to aid drug discovery. For instance, PacBio declares a collaboration with the Genomics England society for the utility of PacBio’s technology to detect genetic variation in unexplained rare disorders. The study is intended to re-sequence a selection of samples collected during Genomics England’s 100,000 genomes project to discover potential operational and clinical benefits of long-read sequencing for the identification of mutations associated with rare diseases.

Market Concentration & Characteristics

Market growth stage is moderate, and pace of the market growth is accelerating. The genomics market is characterized by a moderate-to-high degree of growth owing to increasing investment in R&D programs, advancements in technology, decreasing costs of sequencing, and increasing applications in various fields such as healthcare, agriculture, and personalized medicine. Furthermore, the market is also characterized by ongoing research and development activities, with companies investing in new technologies, methodologies, and applications. This included the development of cell genomics, proteomics, and advancements in bioinformatics. As per IQVIA, the number of genomes studied is predicted to increase to 52 million by 2025, bringing us new potential to treat chronic diseases and assess patient vulnerability to infections like COVID-19.

Key strategies implemented by players in genomics market are new product launches, expansion, acquisitions, partnerships, and other strategies. For instance, in January 2024, Veracyte has announced the acquisition of C2i Genomics to provide minimal residual disease capabilities to their novel diagnostic platform.

Growth of genomic data pool from research studies has helped biologists, patients, and physicians to investigate the genetic predisposition for some of the diseases. The clinical application of this data pool is expected to transform the healthcare system related to the provision of more effective, reliable, and accurate, disease management solutions. Although the clinical use of genomic data is still in the nascent stage, the industrial and healthcare communities are making efforts to successfully incorporate genetic data into clinical workflows.

The genomics market is dynamic and continues to witness constant innovation and translation of scientific knowledge to various applications. For instance, In January 2023, Prenetics Global Limited owned ACT Genomics received the U.S. FDA authorization for ACTOnco, a comprehensive genomic profiling test for solid cancers. It is beneficial for healthcare professionals to make informed clinical decisions related to professional guidelines for patients with solid cancers.

Furthermore, the use of AI-based software for understanding genomic data in various applications is another trend observed in this market and enabling cost-effective and rapid genome sequencing. Furthermore, AI speeds genomic research by automated data processing, enabling massive data integration, and allowing for faster & more accurate analysis. These benefits entice researchers, healthcare professionals, along with pharmaceutical firms, driving market expansion.

Application Insights

The functional genomics segment dominated the overall market with the largest revenue share of 32.1% in 2023. The dominance of the segment can be attributed to research studies aiming to understand a particular phenotypical expression of a given disease condition. Many gene therapies for cancers are designed on the basis of functional genomic technology. For instance, in June 2020, researchers at European Molecular Biology Laboratory (EMBL) at Heidelberg increased the scalability and precision metrics of functional genomics CRISPR/Cas9 gene-based screens through targeted single-cell RNA sequencing. Single-cell RNA sequencing gives deep insights into levels of gene expression in individual cells and can capably analyze CRISPR/Cas9 functional genomics screens.

Pathway analysis segment is predicted to emerge as the most lucrative of all by 2030. Usage of pathway analysis in developing next-generation therapeutics has emerged one of the most growing applications. Pathway-based analysis has gained more attention after the emergence of clinical genomics and personalized therapies. This is mainly because genomics and personalized therapies aid in the in-depth analysis of the ability to navigate signaling pathways and disease networks.

Deliverables Insights

The product segment dominated the market in 2023. The products used in genomics are broadly segmented into two categories—instruments or systems that are required for the synthesis and sequencing of the nucleic acid sequences and consumables & reagents.

The increase in preference for personalized medicines and decline in costs of DNA sequencing owing to the launch of NGS technology resulted in the development of novel products or systems. The genomics market is gradually becoming more competitive with new product launches. For instance, in June 2022, PerkinElmer introduced an automated benchtop system for NGS, the research-use only BioQule NGS System to automate library preparation.

The service segment is expected to register a steady CAGR by 2030. The high cost of products, the demand for expertise required for genomics, and the focus on core operations by the end user are the major factors driving the services segment. NGS-based services held a major share in the genomics services segment due to the rapid adoption of Whole Genome Sequencing (WGS) and applications of sequence databases for disorder screening and prognosis. However, data processing and interpretation, rather than data production has become the need for current development and application. 

End-user Insights

The pharmaceutical and biotechnology companies segment led the market in 2023. This is attributed to the increasing demand for use of genomics in drug discovery. Moreover, the market is driven by increasing adoption of spatial genomics & transcriptomics technologies. Numerous trials are underway for novel drug discovery using underlying knowledge from genomics. For instance, in June 2022, Illumina Inc., declares that it will present seven of their abstracts regarding the key oncology research at the American Society of Clinical Oncology (ASCO) 2022 in further to an event to discuss the transformational impact of comprehensive genomic profiling in precision medicine.

The hospital and clinic segment is estimated to grow at a substantial pace during the forecast period. Several hospitals and clinics are currently offering genomic sequencing services to patients and are using this technology in the daily practice of medicine. Stanford Medicine is one such facility that provides genomic sequencing services to patients with a rare or unidentified condition that is thought to be genetic. The first hospital system to offer the general public services for genetic sequencing, analysis, and interpretation is Partners HealthCare based in the U.S. It has enrolled over 200 patients and physicians in a study funded by NIH to study the integration of whole genome sequencing in clinical medicine.

Regional Insights

North America accounted for the largest market share of 42.65% in 2023. This is attributed to the support of research institutes and pharmaceutical giants. Genomics is now an integral part of any disease research and drug discovery due to the implications of genetic expression on human health. There are emerging advancements in the region for the utility of genomics with collaborative efforts. For instance, in January 2022, Illumina, Inc. collaborated with Nashville Biosciences, LLC, (part of Vanderbilt University Medical Center at Tennesee), for drug development by using genomics and to establish a preeminent clinico-genomic resource.

Asia Pacific is estimated to be the fastest-growing segment over the forecast period due to increased demand for genomics applications in diagnostics and the growing demand for novel therapeutic drugs to fight the increased incidence of diseases in the region. Several major human genome sequencing projects are being performed, one of the most recent projects is Genome Asia 100K. Under this project, 100,000 Asian genomes would be sequenced and analyzed, which can help accelerate population-specific medical advances and precision medicine. With this project, GA 100K was expected to identify new possible therapeutic drugs and understand the biology of diseases.

India Genomics Market

Indian market is anticipated to grow at significant growth rate over the forecast period. Over the past few decades, India has become a hub for pharmaceutical and biotechnology and has gained global attention due to the presence of skilled & knowledgeable manpower and low capital investments. Owing to the presence of rich resources and a large pool of existing R&D institutions in the country, India has become one of the key areas for setting up research laboratories & manufacturing units by multinational companies. Thus, rapidly growing pharmaceutical & biotechnology industries and frequent government initiatives to boost R&D activities in the country are expected to create lucrative opportunities in India genomics market.

Key Companies & Market Share Insights

The market players operating in the genomics market are adopting product approval to increase the reach of their products in the market and improve the availability of their products & services in diverse geographical areas, along with expansion as a strategy to enhance production/research activities. In addition, several market players are acquiring smaller players to strengthen their market position. This strategy enables companies to increase their capabilities, expand their product portfolios, and improve their competencies.

Recent Development

• In November 2023, Fabric Genomics collaborated with DNAnexus and Oxford Nanopore Technologies for deployment of CLIA/CAP labs in pediatric and neonatal ICU’s. The labs will use Oxford Nanopore’s platforms to study genetic disorders in infants.

• in February 2023, Illumina, Inc. entered into a collaboration with African Centre of Excellence for Genomics of Infectious Diseases to start a training institute to increase genomic capabilities in African region

• In January 2023, SOPHiA GENETIC collaborated with the Memorial Sloan Kettering Cancer Center (MSK), a U.S. Cancer Center, to offer researchers and clinicians solutions to expand analytical and testing capabilities.

• In January 2023, Agilent Technologies, Inc. announced acquisition of Avida Biomed, a company that develops target enrichment workflows for clinical researchers utilizing NGS methods to study cancers.

• In April 2022, QIAGEN launched the Biomedical Knowledge Base in Europe, Japan, North America, and Australia to support data science applications in biotech companies 

Genomics Market Report Scope

Global Genomics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the global genomics market based on application, technology, deliverables, end-use, and region:

Application & Technology Outlook (Revenue, USD Billion, 2018 - 2030)

• Functional Genomics

  • Transfection

  • Real-Time PCR

  • RNA Interference

  • Mutational Analysis

  • SNP Analysis

  • Microarray Analysis

• Epigenomics

  • Bisulfite Sequencing

  • Chromatin Immunoprecipitation (ChIP & ChIP-Seq)

  • Methylated DNA Immunoprecipitation (MeDIP)

  • High-Resolution Melt (HRM)

  • Chromatin Accessibility Assays

  • Microarray Analysis

• Pathway Analysis

  • Bead-Based Analysis

  • Microarray Analysis

  • Real-time PCR

  • Proteomics Tools (2-D PAGE; yeast 2-hybrid studies)

• Biomarker Discovery

  • Mass Spectrometry

  • Real-time PCR

  • Microarray Analysis

  • Statistical Analysis

  • Bioinformatics

  • DNA Sequencing

• Others

• Technology Outlook (Revenue, USD Billion, 2018 - 2030)

  • Sequencing

  • PCR

  • Flow Cytometry

  • Microarrays

  • Other technologies

• Deliverables Outlook (Revenue, USD Billion, 2018 - 2030)

  • Products

    • Instruments/Systems/Software

    • Consumables & Reagents

  • Services

    • NGS-based Services

    • Core Genomics Services

    • Biomarker Translation Services

    • Computational Services

    • Others

• End-use Outlook (Revenue, USD Billion, 2018 - 2030)

  • Clinical Research

  • Academic & Government Institutes

  • Hospitals & Clinics

  • Pharmaceutical & Biotechnology Companies

  • Other End Users

• Regional Outlook (Revenue, USD Billion, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • India

    • Japan

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait